Iovance Shares Rally as Survey Points to Strong Amtagvi Demand in Melanoma
A proprietary analyst survey is lifting sentiment around IOVA, but its demand signal is not the same as confirmed sales or market-share data…
Abeona Shares Draw Buy Rating After FDA Approval of FAYUVI Gene Therapy
H.C. Wainwright reiterated a Buy rating on Abeona after FDA approval of partner Ultragenyx’s FAYUVI gene therapy for pediatric patients.
Eli Lilly Shares Rise 3.7% After FDA Clears Once-Weekly Onswik Insulin
FDA approval of once-weekly Onswik lifted LLY shares 3.73%, adding another pillar to Eli Lilly’s diabetes and metabolic-treatment strategy.
Eli Lilly Stock Nears $1,200 After Weekly Insulin Approval and $3.25 Billion InnoCare Deal
Eli Lilly shares reached $1,191.92 after FDA approval of weekly insulin Onswik and a $3.25 billion InnoCare agreement broadened its growth n…
aTyr Pharma's FDA Protocol Alignment Sparks Pre-Market Surge: What Investors Need to Know
aTyr Pharma's stock jumped 9.8% in pre-market trading after FDA trial protocol alignment, highlighting a key milestone for investors.
Eli Lilly's Onswik Approval: A Game Changer for Diabetes Management and Investment Potential
Eli Lilly's recent FDA approval of Onswik represents a significant advancement in diabetes treatment and investment potential, with shares s…
GRAIL Inc. Surges 34%: What Investors Need to Know About the Galleri Test and FDA Approval Odds
GRAIL Inc. stock surged 34% following FDA briefing insights on its Galleri test. Here's what investors should know.
Viking Therapeutics Soars 35%: What This Means for the Biopharma Sector
Viking Therapeutics shares surged 35.67% following positive clinical trial results for its weight loss drug, raising questions for traders.
GRAIL's Rally: Analyzing the Implications of FDA Briefing Docs for Investors
GRAIL Inc. ($GRAL) surged 34% following positive FDA briefing documents, signaling potential growth but with uncertainties ahead.
Moderna's Shares Surge: What Investors Need to Know After FDA Approval
Moderna's shares rose 13.31% after FDA approval of its updated vaccine, signaling strong investor optimism.
GRAIL's Galleri Test: A Step Towards Revolutionizing Cancer Detection?
GRAIL's stock surged 34% after positive FDA briefing papers, signaling a pivotal moment for the Galleri cancer detection test.
Amgen's Dazodalibep: A Game-Changer for Sjögren's Disease?
Amgen's dazodalibep shows promise in treating Sjögren's disease, signaling potential market opportunities and pipeline growth.